Pfizer's Hexavalent GBS Vaccine Clears Phase 1/2, But the Real Test Lies in Defining a Correlate of Protection
核心洞察
Pfizer's 6-valent GBS vaccine candidate GBS6 demonstrated robust immunogenicity and an acceptable safety profile in both non-pregnant and pregnant women in a Phase 1/2 trial published in Nature Medicine.
The study enrolled 216 pregnant participants across South Africa, the UK, and the US, with maternal anti-CPS IgG GMCs at delivery ranging from 0.5 to 22.5 μg/ml versus 0.01–0.05 μg/ml for placebo.
No validated correlate of protection exists for GBS, meaning the FDA has never approved a maternal GBS vaccine and the path to Phase 3 licensure remains uncharted.
A Phase 1/2 trial of Pfizer's hexavalent Group B Streptococcus (搜索) vaccine candidate, GBS6 (PF-06760805) (搜索), has demonstrated robust immunogenicity and an acceptable safety profile in both non-pregnant and pregnant female participants, according to results published in Nature Medicine. The data position the program for Phase 3 planning, but the absence of an established correlate of protection for maternal GBS immunization means the regulatory framework needed to interpret these results does not yet fully exist.
The randomized, placebo-controlled, dose-escalation, observer-blinded study (ClinicalTrials.gov: NCT03765073) evaluated GBS6, an anti-capsular polysaccharide/CRM197 glycoconjugate vaccine covering serotypes Ia, Ib, II, III, IV, and V. These six serotypes collectively account for over 90% of invasive GBS isolates globally, according to WHO genomic surveillance data.
Immunogenicity Results Across Cohorts
In stage 1, 66 non-pregnant participants aged 18–40 were randomized to receive GBS6, GBS6 plus AlPO4, or placebo at the 20-μg dose level. Geometric mean fold rises (GMFRs) from baseline to one month after vaccination ranged from 35.4 (serotype V) to 228.0 (serotype IV) in the GBS6 group. A subset of 26 participants who received a GBS6 plus AlPO4 booster approximately two years after primary vaccination showed antibody levels at one month post-booster that exceeded those at one month post-primary vaccination, suggesting a memory response.
In stage 3, 216 pregnant participants at 24–36 weeks' gestation were enrolled across sites in South Africa, the United Kingdom, and the United States, with 108 each randomized to GBS6 (20-μg dose without AlPO4) or placebo. Maternal anti-CPS IgG geometric mean concentrations (GMCs) at delivery ranged from 0.5 μg/ml to 22.5 μg/ml in the GBS6 group, compared to 0.01–0.05 μg/ml in the placebo group. GMFRs from baseline to one month post-vaccination ranged from 43.8 (serotype V) to 267.7 (serotype IV), similar to responses observed in non-pregnant participants.
Functional opsonophagocytic activity (OPA) responses were also demonstrated, with GMFRs from baseline to one month post-vaccination ranging from 7.0 (serotype V) to 62.0 (serotype Ia) in the GBS6 group. In infants born to vaccinated mothers, OPA geometric mean titers at birth ranged from 393.8 (serotype V) to 3,639.4 (serotype II), compared to 77.1–291.0 in the placebo group.
Placental transfer ratios at delivery ranged from 0.6 for serotype III to 0.8 for serotype IV. Infant anti-CPS IgG GMCs at birth ranged from 0.28 μg/ml to 16.1 μg/ml in the GBS6 group versus 0.01–0.13 μg/ml in the placebo group, with a gradual decline observed through 12 months of age.
Safety Profile
In stage 3 maternal participants, injection site pain was the only local reaction reported, occurring in 30% of GBS6 recipients versus 18% of placebo recipients, all mild or moderate in severity. Fatigue and headache were the most common systemic events, reported in 42% and 37% of GBS6 recipients, respectively, compared to 43% and 38% in the placebo group. No severe systemic events were reported in the GBS6 group.
Serious adverse events occurred in 19% of maternal GBS6 recipients and 21% of placebo recipients, with fetal distress syndrome being the most common SAE. Preterm deliveries occurred in 7.4% of GBS6 recipients and 5.6% of placebo recipients, most of which were late preterm. One stillbirth of unknown cause was reported in the GBS6 group. Two neonatal deaths from neonatal sepsis occurred, one in each group, neither considered related to vaccination. No cases of early-onset or late-onset GBS disease were reported in infants through 12 months of age.
The Regulatory Challenge Ahead
Despite the encouraging data, the path to licensure remains uncertain. The FDA has never approved a maternal GBS vaccine, and no validated correlate of protection exists to define what antibody level in the mother translates to protection in the neonate. The FDA granted GBS6 Breakthrough Therapy Designation on September 7, 2022, which accelerates development through more intensive FDA guidance but does not resolve the correlate-of-protection question.
The Phase 3 design will need to address a specific operational tension: enrolling pregnant women in an efficacy trial large enough to detect a statistically significant reduction in neonatal GBS disease. In the United States, where intrapartum antibiotic prophylaxis has reduced early-onset GBS disease to approximately 1.3 cases per 1,000 live births, powering a neonatal endpoint trial purely on U.S. sites is likely not viable without either an enormous sample size or a global multi-site design weighted toward higher-incidence regions.
The trial's inclusion of pregnant participants in a Phase 1/2 study represents a deliberate regulatory signal, consistent with the FDA's 2018 Task Force on Research Specific to Pregnant Women and 2020 guidance encouraging earlier inclusion of pregnant women in clinical trials. The non-pregnant cohort served as the safety and immunogenicity signal generator, while the pregnant cohort answered the operationally critical questions about immune response during pregnancy and antibody transfer to the neonate.
The publication in Nature Medicine positions Pfizer to begin Phase 3 planning in a disease area where the competitive field remains sparse and regulatory incentives, including Breakthrough Therapy Designation and the downstream possibility of priority review, are in place. However, the window between a clean Phase 1/2 readout and the opening of Phase 3 enrollment is where the difference between a licensed vaccine and a stalled program will be decided—not in the trial itself, but in the regulatory conversations that happen before it starts.